STTK earnings analysis
What we found in STTK's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The supplied extract contains no quarterly income statement, balance-sheet, cash-flow, segment, or MD&A financial data, so revenue, margins, EPS, cash flow, and working-capital trends cannot be assessed from the filing text provided. Management reported effective disclosure controls as of June 30, 2026 and no material changes to the risk factors from the 2025 Form 10-K. The principal incremental item is a director’s potential sale of up to 71,083 shares under a Rule 10b5-1 plan.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Controls Rated Effective
- Management concluded that disclosure controls and procedures were effective at the reasonable-assurance level as of June 30, 2026.
- No Equity Issuance or Buybacks
- The filing reports no unregistered securities sales and no issuer share repurchases during the period; both were reported as “None.”
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Potential Insider Share Sales
- A Rule 10b5-1 plan adopted by director Dr. Neil Gibson provides for potential sales of up to 71,083 common shares and expires no later than February 26, 2027, subject to conditions.
- Risk Factors Unchanged
- The company states there were no material changes to the risk factors disclosed in its 2025 Form 10-K, limiting the filing’s update on company-specific risks.
What they said about what is next.
The supplied 10-Q extract does not provide quantitative revenue or EPS guidance. No outlook, liquidity outlook, or capital-spending forecast was disclosed in the provided text.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 7, 2026
- Shattuck Labs reported zero revenue for Q1 2026, resulting in a net loss of $14.8 million, or $0.13 per share, which reflects a narrower loss compared to $13.7 million, or $0.27 per share, from the prior year. Cash and…
- 10-K · March 5, 2026
- Shattuck Labs positions itself as a clinical-stage immunology biotech developing potentially first-in-class DR3 blocking antibodies, led by SL-325 (1.3 picomolar DR3 affinity). The company reports positive IND‑enabling…
- 10-Q · May 1, 2025
- Shattuck Labs reported Q1 2025 collaboration revenue of $0 versus $1,115 in Q1 2024, driving total revenue to zero. Net loss narrowed to $13,702 (EPS -$0.27) from $18,504 (EPS -$0.37) year-over-year, with lower R&D…
- 10-K · March 27, 2025
- Shattuck Labs positions itself as a developer of first-in-class DR3 antagonist biologics led by SL-325, which it expects to file an IND in the third quarter of 2025 and complete Phase 1 enrollment in the second quarter…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing STTK makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever